Patents by Inventor Hans-Peter Bode

Hans-Peter Bode has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6821289
    Abstract: A safer, improved method of photodynamic therapy is provided for treating diseased, hyperproliferative tissue, including cancer, psoriasis, and arthritis, using multiple, sequential administrations of a photosensitizer (PS) prior to irradiation. Preferred photosensitizers are characterized by being retained in the diseased tissue for a longer time than in normal tissue. The interval between administrations is chosen to be of sufficient duration to allow the PS content of normal tissues to drop to a basal or negligible level before the next administration and before irradiation. At that time, the PS content of the diseased tissue is still high, not less than half of the initial content after the last PS administration. In this way, PDT with better selectivity for the diseased tissue is achieved. With sequential PS administrations, the PS burden on normal tissue can be kept low, so that side effects can be reduced, for example damage of the skin by sunlight or bright indoors artificial lighting.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: November 23, 2004
    Assignee: CeramOptec Industries, Inc.
    Inventors: Hans-Peter Bode, Volker Albrecht
  • Publication number: 20040193233
    Abstract: A safer, improved method of photodynamic therapy is provided for treating diseased, hyperproliferative tissue, including cancer, psoriasis, and arthritis, using multiple, sequential administrations of a photosensitizer (PS) prior to irradiation. Preferred photosensitizers are characterized by being retained in the diseased tissue for a longer time than in normal tissue. The interval between administrations is chosen to be of sufficient duration to allow the PS content of normal tissues to drop to a basal or negligible level before the next administration and before irradiation. At that time, the PS content of the diseased tissue is still high, not less than half of the initial content after the last PS administration. In this way, PDT with better selectivity for the diseased tissue is achieved. With sequential PS administrations, the PS burden on normal tissue can be kept low, so that side effects can be reduced, for example damage of the skin by sunlight or bright indoors artificial lighting.
    Type: Application
    Filed: March 25, 2003
    Publication date: September 30, 2004
    Applicant: CeramOptec Industries, Inc.
    Inventors: Hans-Peter Bode, Volker Albercht
  • Publication number: 20030028227
    Abstract: A pharmaceutical composition, method and apparatus for treatment, diagnosis or both treatment and treatment of hyperproliferative malignant and non-malignant diseases of epithelial tissues is disclosed. The invention comprises local application of the pharmaceutical composition to a predetermined area of the tissue characterized by complete and consistent coverage of the tissue, including irregularly shaped tissue. The pharmaceutical composition consists of an active component, such as a photosensitizer or a precursor thereof, and at least one carrier substance including a viscous fluid, a gel, or a fluid that becomes viscous upon contact with the tissue. The gel's viscosity allows it to adhere to the tissue for a sufficient amount of time to transfer the photosensitizer or precursor. In a preferred embodiment the pharmaceutical composition is sprayed onto the surface of the diseased tissue.
    Type: Application
    Filed: August 20, 2002
    Publication date: February 6, 2003
    Applicant: CeramOptec Industries Inc.
    Inventors: Wolfgang Neuberger, Stefan Spaniol, Hans-Peter Bode, Thierry Patrice, Ludovic Bourre